Key Financial Inc Sells 2,603 Shares of Johnson & Johnson $JNJ

Key Financial Inc trimmed its position in Johnson & Johnson (NYSE:JNJ) by 9.6% in the second quarter, Holdings Channel reports. The fund owned 24,527 shares of the company’s stock after selling 2,603 shares during the quarter. Johnson & Johnson accounts for 0.8% of Key Financial Inc’s portfolio, making the stock its 29th largest holding. Key Financial Inc’s holdings in Johnson & Johnson were worth $3,746,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of JNJ. Brighton Jones LLC lifted its stake in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after acquiring an additional 6,332 shares during the last quarter. Wealth Group Ltd. bought a new position in Johnson & Johnson during the 1st quarter worth $218,000. Smart Money Group LLC raised its position in Johnson & Johnson by 6.5% during the 1st quarter. Smart Money Group LLC now owns 6,687 shares of the company’s stock worth $1,109,000 after purchasing an additional 407 shares during the last quarter. Argyle Capital Management LLC raised its position in Johnson & Johnson by 0.8% during the 1st quarter. Argyle Capital Management LLC now owns 26,004 shares of the company’s stock worth $4,313,000 after purchasing an additional 200 shares during the last quarter. Finally, Element Wealth LLC raised its position in Johnson & Johnson by 5.8% during the 1st quarter. Element Wealth LLC now owns 1,886 shares of the company’s stock worth $313,000 after purchasing an additional 104 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Performance

JNJ stock opened at $186.24 on Tuesday. The stock has a 50-day moving average price of $183.43 and a 200-day moving average price of $167.96. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $194.48. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The firm has a market cap of $448.71 billion, a PE ratio of 17.98, a price-to-earnings-growth ratio of 2.19 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The firm had revenue of $24.02 billion during the quarter. As a group, equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be given a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Analyst Ratings Changes

Several brokerages recently issued reports on JNJ. Loop Capital set a $190.00 target price on Johnson & Johnson in a research report on Wednesday, October 22nd. Stifel Nicolaus raised their target price on Johnson & Johnson from $165.00 to $190.00 and gave the stock a “hold” rating in a research report on Wednesday, October 15th. Bank of America raised their target price on Johnson & Johnson from $198.00 to $204.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 15th. Sanford C. Bernstein raised their target price on Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research report on Monday, October 6th. Finally, Daiwa America raised Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average price target of $199.05.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 0.16% of the stock is currently owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.